Acelity and Mediq Partner to Strengthen Offering in Europe
Exclusive partnership will expand access to Acelitys advanced wound care and regenerative medicine portfolio for patients and clinicians in the Nordic Region
February 16, 2016
Acelity™, a global advanced wound care and regenerative medicine company, today announced a partnership with Mediq to exclusively distribute Acelity’s advanced wound care and regenerative medicine portfolio in Denmark, Finland, Norway and Sweden. The alliance with Mediq, a leading homecare and medical device delivery company, offers Acelity access to Mediq’s specialized knowledge, expertise and network in the region and allows Acelity to expand operations in the post-acute environment.
“This new strategic partnership strengthens and expands our European presence by combining Acelity’s industry-leading portfolio in advanced wound care and regenerative medicine with Mediq’s broad-based distribution network in the region,” said Laura Piccinini, President, Acelity Developed Markets. “Mediq’s scale provides Acelity with unparalleled access to healthcare professionals, ultimately ensuring that our products are more readily available to the patients who need them.”
The partnership leverages Mediq’s extensive experience in increasing access-to-care by offering integrated, high-quality healthcare services in a variety of settings, including hospitals and care institutions, pharmacies and patients’ homes. Under the terms of the agreement, Mediq will exclusively distribute Acelitys advanced wound care and regenerative medicine portfolio, coordinating sales, orders and delivery in Denmark, Finland, Norway and Sweden.
“At Mediq, our focus is on ensuring patients have access to the products and devices that will facilitate their healing whether they receive care in hospital, at home or in a care setting in-between,” said Joergen Kelkjaer, Executive Vice President Nordics & Baltics, Mediq. This partnership with Acelity will allow us to strengthen our offering to the patients we serve by providing them a full range of leading advanced wound care and regenerative medicine products.”
Subject to the appropriate employee consultation processes now underway, the agreement is anticipated to be completed by March 1, 2016.
ACELITY L.P. Inc. and its subsidiaries are a global advanced wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. Available in more than 80 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,800 people around the world.
Mediq is a major player in global healthcare. Mediq has leading market positions in fourteen countries. Every day we improve the lives of millions of people, by providing medical devices, services and pharmaceuticals: at home, with their GP, at their hospital or care institution, or through one of our pharmacies. Mediq’s head office is located in Utrecht, the Netherlands. The company was founded in 1899 and has around 7,100 employees. For more information see
Copyright 2016,2019, KCI Licensing, Inc. All rights reserved.
The information included in this web site has been prepared for and is intended for viewing by residents of the United States of America. This web site contains information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please consult individual country sites for approved uses and any applicable restrictions.
The information in the “Products” and “Healthcare Professionals” sections of this website is intended for healthcare professionals. Patients should consult with their healthcare professional providers regarding their specific medical conditions and treatments as well as the information provided on this site, including the risks and benefits of certain products and services that may be discussed on this site.